Mr. Ronnie Andrews serves as President of Medical Sciences at Life Technologies. Mr. Andrews has more than 25 years of experience in the diagnostics industry, including leadership positions at companies such as GE Healthcare, Clarient, Abbott Diagnostics and Roche Diagnostics. Mr. Andrews applies his expertise to expand Life Technologies' presence in the diagnostics and personalized medicine space through strategies including short and long term partnerships. Mr. Andrews served as Chief Executive Officer Clarient and Segment Leader, GE Molecular Diagnostics and led integration of Clarient, maintaining 20 per cent annual growth and establishing a strategic plan to expand GE's presence in oncology diagnostics. Mr. Andrews also served as the Chief Executive Officer at Clarient. He led the organization from $6MM in annual revenue to $120MM and raised more than $50MM in capital to fund growth, obtained exclusive licenses for oncology biomarkers and successfully launched new molecular tests for cancers, including leukemia and melanoma. Mr. Andrews also served Roche Molecular Diagnostics as Senior Vice President of Global Marketing and Commercial Business Operations. He directed annual growth rates of 20 per cent and was instrumental in building Roche's HIV molecular testing business, establishing molecular as the gold standard for infectious disease testing. He is a Member of Life Sciences Advisory Board at Safeguard Scientifics, Inc.
The Budget Control Act would be a hard hit to federal R&D investments in life sciences, aerospace, defense and more, with significant long-term consequences to economic growth.